ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 436

December 28, 1984

MULTIPLE SCLEROSIS: EXPERIMENTAL AND CLINICAL ASPECTS[a]

Editors and Conference Organizers

LABE SCHEINBERG and CEDRIC S. RAINE

CONTENTS

Preface. *By* LABE SCHEINBERG and CEDRIC S. RAINE xi

Opening Remarks. *By* SYLVIA LAWRY 1

Part I. Pathogenetic Mechanisms

Recent Advances in Myelin Biochemistry. *By* WILLIAM T. NORTON 5

Continual Breakdown and Regeneration of Myelin in Progressive Multiple Sclerosis Plaques. *By* J. W. PRINEAS, E. E. KWON, EUN-SOOK CHO, and L. R. SHARER 11

Experimental Autoimmune Demyelination: Chronic Relapsing Models and Their Therapeutic Implications for Multiple Sclerosis. *By* CEDRIC S. RAINE and UTE TRAUGOTT 33

The Current Status of Multiple Sclerosis Intra-Blood-Brain-Barrier IgG Synthesis. *By* WALLACE W. TOURTELLOTTE, MICHAEL J. WALSH, ROBERT W. BAUMHEFNER, SUSAN M. STAUGAITIS, and PAUL SHAPSHAK 52

Pathophysiology of Demyelination. *By* MICHAEL RASMINSKY 68

General Discussion 81

Mechanisms and Consequences of Virus Persistence in the Human Nervous System. *By* V. TER MEULEN, M. J. CARTER, H. WEGE, and R. WATANABE 86

Demyelination and Remyelination in Murine Viral Encephalomyelitis. *By* W. LANG, M. RODRIGUEZ, V. A. LENNON, and P. W. LAMPERT 98

Detection by Hybridization of Viral Infection of the Human Central Nervous System. *By* ASHLEY T. HAASE, LINDA STOWRING, PETER VENTURA, JACK BURKS, GEORGE EBERS, WALLACE TOURTELLOTTE, and KENNETH WARREN 103

[a]The papers in this volume were presented at a conference entitled Multiple Sclerosis: Theory and Practice, which was held by the New York Academy of Sciences on November 29 to December 1, 1983.

Multiple Sclerosis: Epidemiology and HLA Associations. *By* W. I. McDonald 109

Family and Twin Studies in Multiple Sclerosis. *By* Henry F. McFarland, Jeffrey Greenstein, Dale E. McFarlin, Roswell Eldridge, Xian-hau Xu, and Helen Krebs 118

Pathogenetic Mechanisms in Multiple Sclerosis: A Summary. *By* Byron H. Waksman 125

General Discussion 130

Part II. Immunology of Multiple Sclerosis

Immunoregulation in Multiple Sclerosis. *By* Barry G. W. Arnason, Jack P. Antel, and Anthony T. Reder 133

Indicators of Disease Activity in Multiple Sclerosis: Studies of Myelin Basic Protein-like Materials. *By* John N. Whitaker 140

Characterization of Cerebrospinal Fluid Lymphocytes in Multiple Sclerosis. *By* John R. Richert, John W. Rose, Xian-hau Xu, Jeffrey I. Greenstein, Henry F. McFarland, and Dale E. McFarlin 151

Further Lymphocyte Characterization in the Central Nervous System in Multiple Sclerosis. *By* Ute Traugott and Cedric S. Raine 163

Studies of Interferon Production and Natural Killing by Lymphocytes from Multiple Sclerosis Patients. *By* P. Andrew Neighbour 181

Cytotoxic Cells in Peripheral Blood and Cerebrospinal Fluid of Multiple Sclerosis Patients. *By* Jean E. Merrill, Lawrence W. Myers, and George W. Ellison 192

Oligoclonal Banding in MS. *By* George C. Ebers 206

Antibodies to Glycosphingolipids in Patients with Multiple Sclerosis. *By* Tamao Endo, S. Scott Stewart, Samar K. Kundu, Susan Osovitz, and Donald M. Marcus 213

Immune Responses to Myelin Antigens in Multiple Sclerosis. *By* Robert P. Lisak, Burton Zweiman, James B. Burns, Abdolmohammad Rostami, and Donald H. Silberberg 221

General Discussion 231

Part III. Clinical Manifestations of Multiple Sclerosis

Taxonomy and Diagnostic Parameters in Multiple Sclerosis. *By* Charles M. Poser 233

Panel Presentations on Diagnostic Values of Blood T Cell Levels in Multiple Sclerosis

T Regulator Cell Surface Antigens in Multiple Sclerosis. *By* Anthony T. Reder, Jack P. Antel, and Barry G. W. Arnason 247

Evaluation of Leukocyte Surface Antigens in Patients with Multiple Sclerosis. *By* D. E. McFarlin and E. S. Mingioli 254

Suppressor T Cells in MS: Do Changes in Numbers Vary with Clinical Activity? *By* D. W. Paty and L. F. Kastrukoff 266

The Failure of Monoclonal Antibody-defined Lymphocyte Subsets to Monitor Disease Activity in Patients with Multiple Sclerosis. *By* GEORGE P. A. RICE, JACK C. SIPE, SHERRY L. BRAHENY, ROBERT L. KNOBLER, DAVID A. FINNEY, and MICHAEL B. A. OLDSTONE 271

T Cell Subsets in Patients with Multiple Sclerosis: An Overview. *By* HOWARD L. WEINER, DAVID A. HAFLER, ROBERT J. FALLIS, DAVID JOHNSON, KENNETH A. AULT, and STEPHEN L. HAUSER 281

General Discussion 291

Magnetic Resonance Imaging and CT Scanning in Multiple Sclerosis. *By* BURTON P. DRAYER and LYNN BARRETT 294

Pattern-Shift Visual, Brainstem Auditory and Short-Latency Somatosensory Evoked Potentials in Multiple Sclerosis. *By* KEITH H. CHIAPPA 315

Multiple Sclerosis Bladder: Studies and Care. *By* JERRY G. BLAIVAS, NANCY J. HOLLAND, BARBARA GIESSER, NICHOLAS LAROCCA, MICHELE MADONNA, and LABE SCHEINBERG 328

Part IV. Clinical Trials in Multiple Sclerosis

Disability Rating Scales in Multiple Sclerosis. *By* JOHN F. KURTZKE 347

Panel Presentations on Therapeutic Trials in Multiple Sclerosis

Therapeutic Trials in Multiple Sclerosis: Azathioprine. *By* GEORGE W. ELLISON, LAWRENCE W. MYERS, M. RAY MICKEY, MARGARET V. FRANE, WALLACE W. TOURTELLOTTE, CELSA A. SPINA, and JOHN L. FAHEY 361

Clinical Trials of Copolymer I in Multiple Sclerosis. *By* M. B. BORNSTEIN, A. I. MILLER, S. SLAGLE, R. ARNON, M. SELA, and D. TEITELBAUM 366

The Use of Cyclophosphamide in the Treatment of Multiple Sclerosis. *By* HOWARD L. WEINER, STEPHEN L. HAUSER, DAVID A. HAFLER, ROBERT J. FALLIS, JAMES R. LEHRICH, and DAVID A. DAWSON 373

Clinical Trial of Natural Alpha Interferon in Multiple Sclerosis. *By* ROBERT L. KNOBLER, HILLEL S. PANITCH, SHERRY L. BRAHENY, JACK C. SIPE, GEORGE P. A. RICE, JOHN R. HUDDLESTONE, GORDON S. FRANCIS, CAROL J. HOOPER, ROBERTA M. KAMIN-LEWIS, KENNETH P. JOHNSON, MICHAEL B. A. OLDSTONE, and THOMAS C. MERIGAN 382

Plasmapheresis and Combined Immunosuppressive Drug Therapy in Chronic Progressive Multiple Sclerosis: Choosing the Patient Who Should Respond. *By* BHUPENDRA O. KHATRI, MICHAEL P. MCQUILLEN, and SUSAN KOETHE 389

Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis: A Preliminary Report. *By* M. P. HAFSTEIN, C. DEVEREUX, R. TROIANO, G. ZITO, R. VIDAVER, P. C. DOWLING, M. LAVENHAR, and S. D. COOK 397

Intrathecal IgG Synthesis and IgG Index after Intensive and Chronic Immunosuppressive Treatment of Multiple Sclerosis. *By* O. R. HOMMES, K. J. B. LAMERS, and W. VAN GEEL 410

Clinical Trials in Multiple Sclerosis: Problems and Opportunities. *By* DONALD H. SILBERBERG 418

General Discussion 423

Part V. Psychosocial and Economic Features in MS

The Current Management of Multiple Sclerosis. *By* RANDALL T. SCHAPIRO, STANLEY VAN DEN NOORT, and LABE SCHEINBERG 425

Psychosocial Factors in Multiple Sclerosis and the Role of Stress. *By* NICHOLAS G. LAROCCA 435

Sexual Dysfunctions in Multiple Sclerosis. *By* GEORGE SZASZ, D. PATY, and W. L. MAURICE 443

Development and Testing of a Minimal Record of Disability in Multiple Sclerosis. *By* ROBERT J. SLATER, NICHOLAS G. LAROCCA, and LABE C. SCHEINBERG 453

The National Multiple Sclerosis Survey: Background and Economic Impact. *By* FREDERIC D. WEINFELD and HERBERT M. BAUM 469

General Discussion 471

The Future of Funding for MS Research. *By* THOR HANSON 472

Poster Papers

Multiple Sclerosis and Epstein-Barr Virus: Guilt by Association? *By* HELEN B. WARNER 475

Fcγ Receptors in Multiple Sclerosis Brains. *By* HARALD NYLAND, SVERRE MØRK, and ROALD MATRE 476

Long-Term Culture of Bulk Isolated Adult Human Oligodendrocytes. *By* SEUNG U. KIM, GIUSEPPE MORETTO, DOO H. SHIN, and DONALD W. PATY 480

Early Experience in Nuclear Magnetic Resonance Imaging of Multiple Sclerosis. *By* D. LI, J. MAYO, S. FACHE, W. D. ROBERTSON, D. PATY, and M. GENTON 483

Electrophysiological Confirmation of Orientation-specific Contrast Losses in Multiple Sclerosis. *By* MARK J. KUPERSMITH, JEREMIAH I. NELSON, WILLIAM H. SEIPLE, and RONALD E. CARR 487

A Monoclonal Antibody for Astrocytes. *By* S. K. MALHOTRA, F. WONG, N. SINHA, V. MANICKEVAL, T. K. SHNITKA, and K. G. WARREN 492

Neuropsychological Studies in Chronic Progressive Multiple Sclerosis. *By* STEPHEN M. RAO, THOMAS A. HAMMEKE, SANDER GLATT, MICHAEL P. MCQUILLEN, B. O. KHATRI, ANNE MARIE RHODES, and SUSAN POLLARD 495

Copolymer I: Effect on Normal Human Lymphocytes. *By* C. F. BROSNAN, M. LITWAK, P. A. NEIGHBOUR, and M. B. BORNSTEIN 498

Metabolic Pathology of Brain Inflammation. *By* RICHARD J. DIROCCO 500

A Murine Model of Herpes Simplex Virus Type 1 of the Nervous System. *By* LORNE F. KASTRUKOFF, ALLEN S. LAU, and DONALD W. PATY 504

Reduced $OKT8^+$ and $OKT3^+$ Cells in Blood of Progressive MS Patients. *By* J. OGER, S. JACKEVICIUS, J. P. ANTEL, and B. G. ARNASON 506

CSF Antibrain Antibodies in Neurologic Diseases. *By* A. A. VANDENBARK, F. VAN ROMPAEY, D. NIJST, H. OFFNER, H. HEYLIGEN, and J. RAUS ... 508

Characterization of Antigen-specific T Cells in Multiple Sclerosis Twins with Elevated Responses to Measles Virus. *By* J. I. GREENSTEIN, S. JACOBSON, J. R. RICHERT, and H. F. MCFARLAND 511

The National Neurological Research Bank: A Collection of Cryopreserved Human Neurological Specimens for Neuroscientists. *By* W. W. TOURTELLOTTE, H. H. ITABASHI, I. ROSARIO, and K. BERMAN 513

Index of Contributors 517

Financial assistance was received from:

- The Schmulka Aronson Charitable Trust
- CIBA-GEIGY Corporation
- Davis, Brody and Associates
- Mr. and Mrs. Andrew Golden
- Mr. Clifford Goldsmith
- Hoffmann-La Roche, Inc.
- Mr. and Mrs. Irving Moskovitz
- National Institute of Handicapped Research
  Research and Demonstration Project (no. G008006808)
  Comprehensive Continuing Care and Rehabilitation Program for MS Patients and Medical Rehabilitation Research and Training Center for MS (no. G008300040)
- National Multiple Sclerosis Society
- National Multiple Sclerosis Society—New York City Chapter
- Paralyzed Veterans of America
- Mr. and Mrs. William Rybnick
- Mr. and Mrs. Gerald Stern
- The Upjohn Company

The New York Academy of Sciences believes that it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the authors of the papers that make up this *Annal* are their own and not those of the Academy. The Academy has no intent to influence legislation by providing such forums.